{"Clinical Trial ID": "NCT00971945", "Intervention": ["INTERVENTION 1:", "Treatment arms", "Paclitaxel 100 mg/m2 IV administered on days 1, 8, 15, 22, 29, 36 then suspended until day 49 (1 course including 49 days)."], "Eligibility": ["Incorporation criteria:", "Subjects who have been confirmed to have a response after receiving at least two weekly paclitaxel treatments and considered to be in need of further investigation/under-research among patients with advanced or recurrent breast cancer who had met the screening criteria and had participated in the previous Phase II clinical study"], "Results": ["Performance measures:", "Number of participants experiencing adverse events", "This result describes the number of participants who experience any type, class, cause of adverse events (assessed both subjectively and objectively)", "Time: from the first dose to the end of the follow-up period (up to about 33 months)", "Results 1:", "Title of arm/group: Treatment arm", "Description of the arm/group: Paclitaxel 100 mg/m2 IV given on days 1, 8, 15, 22, 29, 36 and then suspended until day 49 (1 course including 49 days).", "Total number of participants analysed: 6", "Type of measure: Number of participants", "Unit of measure: Participants 6,100.0%"], "Adverse Events": ["Undesirable Events 1:", "Total: 2/6 (33.33 per cent)", "Nausea 1/6 (16.67%)", "Vomiting 1/6 (16.67%)", "1/6 (16.67%)"]}